Precision Biosciences (DTIL) Non-Current Deferred Tax Liability (2018 - 2019)
Precision Biosciences (DTIL) posted quarterly Non-Current Deferred Tax Liability of $1.5 million for Q4 2019, up 149.66% year-over-year from $586000.0 in Q4 2018, and up 149.66% quarter-over-quarter from $586000.0 in Q4 2018.
Precision Biosciences (DTIL) Non-Current Deferred Tax Liability (2018 - 2019) Analysis & Trends
Precision Biosciences (DTIL) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $1.5 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Non-Current Deferred Tax Liability rose 149.66% year-over-year to $1.5 million; the TTM figure through Dec 2019 stood at $1.5 million (up 149.66% YoY), while the FY2019 annual figure was $1.5 million, up 149.66% from the prior year.
- Non-Current Deferred Tax Liability advanced to $1.5 million in Q4 2019 per DTIL's latest filing, from $586000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.5 million in Q4 2019 and bottomed at $586000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 1.46 Mn |
| Dec 31, 2019 | 1.46 Mn |
| Dec 31, 2018 | 586,000.00 |
| Dec 31, 2018 | 586,000.00 |